FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
GY-85B CIP2
APPLICATION NO.
10/630,278
APPLICANT
Wang et al.
FILING DATE
July 30, 2003

Group –

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
EB	AA	5,124,327	6/23/92	W. J. Greenlee, et al			
EB	AB	5,424,329	6/13/95	D. H. Boschelli, et al			
EB	AC	5,023,265	6/11/91	M. H. Scherlock, et al			
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
EB	AI	WO 00/76521A1	12/21/00	PCT Application			☐	☐
	AJ	EP 0530907A1	3/10/93	European Patent Application			☐	☐
	AK	WO 93/01181	1/21/93	PCT Application			☐	☐
	AL	WO 95/04742	2/16/95	PCT Application			☐	☐
	AM	WO 96/11929	4/25/96	PCT Application			☐	☐
	AN	WO 00/71535	11/30/00	PCT Application			☐	☐
↓	AO	WO 01/62255	8/30/01	PCT Application			☐	☐
	AP						☐	☐
	AQ						☐	☐
	AR						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

EB	AS	M. Font, et al, "Indoles and Pyridazino[4,5-*b*]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase," EUR. J . MED. CHEM., **30**, pp. 963-971, 1995
EB	AT	D. L. Romero, et al, J. MED. CHEM., **36**, pp. 1505-1508, 1993
EB	AU	S. D. Young, et al, "2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, **5**(5), pp. 491-496, 1995

EXAMINER E Bernhardt **DATE CONSIDERED** 4/19/04

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. GY-85B CIP2
APPLICATION NO. 10/630,278
APPLICANT Wang et al.
FILING DATE July 30, 2003
Group --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

EB	AV	M. J. Genin, et al, "Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs," J. MED. CHEM., **39**, pp. 5267-5275, 1996
EB	AW	R. Silvestri, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, **9**, pp. 139-148, 1998
EB	AX	A. Fredenhagen, et al, "Semicochliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the Fungus *Chrysosporium Merdarium*," JOURNAL OF ANTIBIOTICS, **50**(5), pp. 395-401, 1997
EB	AY	M. Kato, et al, "New 5-HT_3 (Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives," CHEM. PHARM. BULL., **43**(8), pp. 1351-1357, 1995
EB	AZ	V. Levacher, et al, "Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo [2,3-b]Pyridine Derivatives," TETRAHEDRON, **47**(3), pp. 429-440, 1991
	BA	
	BB	
	BC	
	BD	
	BE	
	BF	
	BG	
	BH	

EXAMINER E Bernhardt | **DATE CONSIDERED** 4/19/04

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.